BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vankadara S, Wong YX, Liu B, See YY, Tan LH, Tan QW, Wang G, Karuna R, Guo X, Tan ST, Fong JY, Joy J, Chia CSB. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors. Bioorg Med Chem Lett 2021;48:128263. [PMID: 34271072 DOI: 10.1016/j.bmcl.2021.128263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Vankadara S, Dawson MD, Fong JY, Oh QY, Ang QA, Liu B, Chang HY, Koh J, Koh X, Tan QW, Joy J, Chia CSB. A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00260] [Reference Citation Analysis]
2 Alugubelli YR, Geng ZZ, Yang KS, Shaabani N, Khatua K, Ma XR, Vatansever EC, Cho CC, Ma Y, Xiao J, Blankenship LR, Yu G, Sankaran B, Li P, Allen R, Ji H, Xu S, Liu WR. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. Eur J Med Chem 2022;240:114596. [PMID: 35839690 DOI: 10.1016/j.ejmech.2022.114596] [Reference Citation Analysis]
3 Yang KS, Leeuwon SZ, Xu S, Liu WR. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. J Med Chem 2022. [PMID: 35731933 DOI: 10.1021/acs.jmedchem.2c00404] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
4 Xu T, Xu M, Zhu W, Chen CZ, Zhang Q, Zheng W, Huang R. Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling. J Med Chem 2022. [PMID: 35275639 DOI: 10.1021/acs.jmedchem.1c01372] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Johansen-leete J, Ullrich S, Fry SE, Frkic R, Bedding MJ, Aggarwal A, Ashhurst AS, Ekanayake KB, Mahawaththa MC, Sasi VM, Luedtke S, Ford DJ, O'donoghue AJ, Passioura T, Larance M, Otting G, Turville S, Jackson CJ, Nitsche C, Payne RJ. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. Chem Sci . [DOI: 10.1039/d1sc06750h] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 Macip G, Garcia-Segura P, Mestres-Truyol J, Saldivar-Espinoza B, Pujadas G, Garcia-Vallvé S. A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet? Int J Mol Sci 2021;23:259. [PMID: 35008685 DOI: 10.3390/ijms23010259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chia CSB, Xu W, Shuyi Ng P. A Patent Review on SARS Coronavirus Main Protease (3CLpro ) Inhibitors. ChemMedChem 2021. [PMID: 34651447 DOI: 10.1002/cmdc.202100576] [Cited by in F6Publishing: 3] [Reference Citation Analysis]